Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TUBB1 | Q9H4B7 | 2/20 | 0.40 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | RELA | Q04206 | 2/20 | 0.38 |
| ▸ | ESR1 | P03372 | 2/20 | 0.37 |
| ▸ | ABL1 | P00519 | 1/20 | 0.37 |
| ▸ | TTR | P02766 | 1/20 | 0.37 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.37 |
| ▸ | BCR | P11274 | 1/20 | 0.37 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.37 |
| ▸ | NQO2 | P16083 | 1/20 | 0.37 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.37 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.37 |
| ▸ | TUBB | P07437 | 1/20 | 0.37 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.37 |
| ▸ | AHR | P35869 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17748803 | 1.00 | TUBB1 (0.40) | TUBB1ALOX5PTGS2PTGS1KCNH2 | |
| SCHEMBL19491867 | 0.93 | TUBB1 (0.39) | TUBB1ALOX5PTGS2PTGS1KCNH2 | |
| SCHEMBL9954884 | 0.83 | SLC6A4 (0.46) | RELARAB9ASLC6A4LMNATDP1 | |
| SCHEMBL9954880 | 0.83 | SLC6A4 (0.46) | RELARAB9ASLC6A4LMNATDP1 | |
| SCHEMBL23779783 | 0.78 | TLR4 (0.45) | AHR | |
| SCHEMBL23779782 | 0.78 | TLR4 (0.45) | AHR | |
| SCHEMBL29185869 | 0.78 | SLC6A4 (0.34) | SLC6A4 | |
| SCHEMBL29185850 | 0.78 | SLC6A4 (0.34) | SLC6A4 | |
| SCHEMBL9928581 | 0.75 | CYP3A4 (0.57) | TUBB1ALOX5PTGS2KCNH2RELA | |
| SCHEMBL7149958 | 0.73 | GABRA1 (0.41) | ALOX5PTGS2PTGS1ESR1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3218458-B1 | IMPROVMENTS IN OR RELATING TO ORGANIC COMPOUNDS | GIVAUDAN SA (CH) | 2019-01-02 | — | — | EP | claimed |
| US-20170298292-A1 | IMPROVEMENTS IN OR RELATING TO ORGANIC COMPOUNDS | GIVAUDAN S.A. (CH) | 2017-10-19 | — | — | US | claimed |
| EP-3218458-A1 | IMPROVMENTS IN OR RELATING TO ORGANIC COMPOUNDS | Givaudan S.A. (CH) | 2017-09-20 | — | — | EP | claimed |
| WO-2016074699-A1 | IMPROVMENTS IN OR RELATING TO ORGANIC COMPOUNDS | GIVAUDAN SA (CH) | 2016-05-19 | — | — | WO | claimed |
| EP-3218458-B1 | IMPROVMENTS IN OR RELATING TO ORGANIC COMPOUNDS | GIVAUDAN SA (CH) | 2019-01-02 | — | — | EP | disclosed |
| EP-3218458-B1 | IMPROVMENTS IN OR RELATING TO ORGANIC COMPOUNDS | GIVAUDAN SA (CH) | 2019-01-02 | — | — | EP | disclosed |
| US-10119097-B2 | Organic compounds | GIVAUDAN S.A. (CH) | 2018-11-06 | — | — | US | disclosed |
| US-20170298292-A1 | IMPROVEMENTS IN OR RELATING TO ORGANIC COMPOUNDS | GIVAUDAN S.A. (CH) | 2017-10-19 | — | — | US | disclosed |
| US-20170298292-A1 | IMPROVEMENTS IN OR RELATING TO ORGANIC COMPOUNDS | GIVAUDAN S.A. (CH) | 2017-10-19 | — | — | US | disclosed |
| US-20170298292-A1 | IMPROVEMENTS IN OR RELATING TO ORGANIC COMPOUNDS | GIVAUDAN S.A. (CH) | 2017-10-19 | — | — | US | disclosed |
| EP-3218458-A1 | IMPROVMENTS IN OR RELATING TO ORGANIC COMPOUNDS | Givaudan S.A. (CH) | 2017-09-20 | — | — | EP | disclosed |
| WO-2016074699-A1 | IMPROVMENTS IN OR RELATING TO ORGANIC COMPOUNDS | GIVAUDAN SA (CH) | 2016-05-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10119097-B2 | Organic compounds | OR10J3, CBR3, C9 | TUBB1 1029/4885ALOX5 228/4885PTGS2 1229/4885 |
| US-20170298292-A1 | IMPROVEMENTS IN OR RELATING TO ORGANIC COMPOUNDS | OR10J3, C5, CBR3 | TUBB1 784/4885ALOX5 224/4885PTGS2 1091/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.